These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9506547

  • 1. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
    Schneider JS, Van Velson M, Menzaghi F, Lloyd GK.
    Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
    [Abstract] [Full Text] [Related]

  • 2. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
    Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK.
    J Pharmacol Exp Ther; 1999 Aug; 290(2):731-9. PubMed ID: 10411585
    [Abstract] [Full Text] [Related]

  • 3. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
    Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK.
    Mov Disord; 1998 Jul; 13(4):637-42. PubMed ID: 9686767
    [Abstract] [Full Text] [Related]

  • 4. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Schneider JS, Tinker JP, Menzaghi F, Lloyd GK.
    J Pharmacol Exp Ther; 2003 Jul; 306(1):401-6. PubMed ID: 12721323
    [Abstract] [Full Text] [Related]

  • 5. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.
    Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND.
    Brain Res; 2008 Oct 09; 1234():16-24. PubMed ID: 18692487
    [Abstract] [Full Text] [Related]

  • 7. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN.
    J Pharmacol Exp Ther; 1999 Sep 09; 290(3):1034-40. PubMed ID: 10454475
    [Abstract] [Full Text] [Related]

  • 8. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov 09; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 9. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 09; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 10. Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
    Kulak JM, Schneider JS.
    Brain Res; 2004 Mar 05; 999(2):193-202. PubMed ID: 14759498
    [Abstract] [Full Text] [Related]

  • 11. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 05; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 12. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
    Decamp E, Schneider JS.
    Eur J Neurosci; 2006 Oct 05; 24(7):2098-104. PubMed ID: 17067307
    [Abstract] [Full Text] [Related]

  • 13. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 14. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 15. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T.
    Adv Neurol; 1993 Sep 28; 60():113-8. PubMed ID: 8093573
    [No Abstract] [Full Text] [Related]

  • 16. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 17. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH, Henry B, Hill M, Crossman A, Brotchie J.
    Mov Disord; 2002 Nov 10; 17(6):1180-7. PubMed ID: 12465055
    [Abstract] [Full Text] [Related]

  • 18. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M, Fukuda T.
    Adv Neurol; 1993 Nov 10; 60():119-22. PubMed ID: 8093574
    [No Abstract] [Full Text] [Related]

  • 19. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Bélanger N, Grégoire L, Bédard PJ, Di Paolo T.
    Neurobiol Aging; 2006 Nov 10; 27(11):1684-93. PubMed ID: 16253392
    [Abstract] [Full Text] [Related]

  • 20. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar 10; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.